Publications by authors named "J Padin"
Article Synopsis
- SARS-CoV-2 infection leads to a wide range of symptoms, with most individuals experiencing mild to moderate cases while a minority develop severe illness requiring intensive care.
- Researchers have focused on identifying biomarkers linked to the severity of the disease and long-COVID, but little is known about the persistence of these biomarkers years after recovery.
- A study found that even two years after infection, specific biomarkers related to severe COVID-19 were still present in asymptomatic patients, indicating lasting changes in the nasopharyngeal area and suggesting a connection between biomarker presence and the severity of prior infection.
Proteases are produced and released in the mucosal cells of the respiratory tract and have important physiological functions, for example, maintaining airway humidification to allow proper gas exchange. The infectious mechanism of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), takes advantage of host proteases in two ways: to change the spatial conformation of the spike (S) protein via endoproteolysis (e.g.
View Article and Find Full Text PDFAprotinin is a broad-spectrum inhibitor of human proteases that has been approved for the treatment of bleeding in single coronary artery bypass surgery because of its potent antifibrinolytic actions. Following the outbreak of the COVID-19 pandemic, there was an urgent need to find new antiviral drugs. Aprotinin is a good candidate for therapeutic repositioning as a broad-spectrum antiviral drug and for treating the symptomatic processes that characterise viral respiratory diseases, including COVID-19.
View Article and Find Full Text PDFNeuropathic pain (NP) is a challenging condition to treat, as the need for new drugs to treat NP is an unmet goal. We investigated the analgesic potential of a new sulfated disaccharide compound, named BIS014. Oral administration (p.
View Article and Find Full Text PDFAprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Eur J Clin Invest
June 2022
Background: SARS-CoV-2 virus requires host proteases to cleave its spike protein to bind to its ACE2 target through a two-step furin-mediated entry mechanism. Aprotinin is a broad-spectrum protease inhibitor that has been employed as antiviral drug for other human respiratory viruses. Also, it has important anti-inflammatory properties for inhibiting the innate immunity contact system.
View Article and Find Full Text PDF